Javed Iqbal, MD
Neurology · Las Cruces, NMNPI 1235123605
Payments from drug & device makers
Across 480 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- UCB, Inc.$673
- AbbVie$649
- Biogen$571
- Genentech USA, Inc.$456
- AstraZeneca$427
- plus $4K from 44 others
What the payments were for
- Speaking & faculty fees$641%
- Food & beverage$7,07870%
- Education$1812%
- Gifts$2,73327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GILENYA$2,670
How this compares
$10,056 in reported general payments places this provider in the 85th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 189 | $236,639 |
| MayzentSiponimod | 17 | $163,452 |
| AustedoDeutetrabenazine | 13 | $155,514 |
| IngrezzaValbenazine Tosylate | 14 | $132,796 |
| Aimovig AutoinjectorErenumab-Aooe | 140 | $128,014 |
| UbrelvyUbrogepant | 69 | $80,210 |
| AptiomEslicarbazepine Acetate | 44 | $69,620 |
| RytaryCarbidopa/Levodopa | 83 | $50,999 |
| Emgality PenGalcanezumab-Gnlm | 52 | $41,038 |
| XcopriCenobamate | 30 | $35,830 |
| Memantine Hcl | 1,317 | $35,373 |
| GlatopaGlatiramer Acetate | 14 | $34,400 |
| FycompaPerampanel | 24 | $30,163 |
| Nurtec OdtRimegepant Sulfate | 20 | $28,915 |
| Levetiracetam | 722 | $25,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Namzaric, Qulipta | $649 | $348,550294 claims |
| NovartisMayzent | $2,963 | $163,45217 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $282 | $155,51413 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $330 | $132,79614 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $212 | $69,62044 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $262 | $58,656172 claims |
| UCB, Inc.Nayzilam, Briviact | $673 | $40,29327 claims |
| SK Life Science, Inc.Xcopri | $126 | $35,83030 claims |
| Eisai Inc.Fycompa | $194 | $30,16324 claims |
| PfizerNurtec Odt | $106 | $28,91520 claims |
| Upsher-smith Laboratories LLCTopiramate | $345 | $6,714423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 91 neurology providers in New Mexico.
Other neurology in Las Cruces
- Rocco FrancoLas Cruces$822
- Gregory CharltonLas Cruces$283
- Corey FordAlbuquerque$6.6M
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Weiwei DaiRio Rancho$367K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.